161BR, Scientist / Associate Scientist, Hematopoietic Differentiation and Translation

Scientist / Associate Scientist, Hematopoietic Differentiation and Translation
Job Code 161BR

Fate’s Hematopoietic Differentiation and Translation team is currently seeking a skilled and motivated cell biologist to support the company’s off-the-shelf cellular immunotherapy translational programs. The successful candidate will join a multidisciplinary team pursuing the derivation of hematopoietic cells, particularly engineered hematopoietic progenitor stem cells (eHPSCs), from iPSCs for cellular therapeutic purposes. The candidate will perform, optimize and analyze experiments involving the in vitro differentiation, expansion and production of iPSCs towards eHPSCs. Candidates must have extensive cell culture experience, in particular with embryonic stem cells (ESCs) or iPSCs, and a knowledge of the hematopoietic system and immunology is preferred. This position will require independent research and coordination with the company’s iPSC engineering and reprogramming team, as well as process development groups. This is a full-time position and is located at our corporate headquarters in San Diego, CA.

Download a PDF of the job description for more details:
pdf version161BR, Scientist / Associate Scientist, Hematopoietic Differentiation and Translation

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 161BR.

About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.